Abbott Laboratories (ABT) operating KPIs
Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%
Abbott Laboratories continuous Glucose Monitoring (CGM — FreeStyle Libre & Lingo) Worldwide Revenue ($M) ($M)
Abbott's flagship biowearable franchise ($7.6B in FY2025, >94% of Diabetes Care revenue). Missing standalone quarters in 10-Q/10-K are split via 6M − Q1, 9M − 6M, and FY − 9M.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Continuous Glucose Monitoring (CGM — FreeStyle Libre & Lingo) Worldwide Revenue ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 7,600 | +18.8% | SEC Filing (0001628280-26-010185) ↗ |
| FY2024 | Dec 31, 2024 | 6,400 | +20.8% | SEC Filing (0001628280-26-010185) ↗ |
| FY2023 | Dec 31, 2023 | 5,300 | +23.3% | SEC Filing (0001628280-25-007110) ↗ |
| FY2022 | Dec 31, 2022 | 4,300 | +16.2% | SEC Filing (0001628280-24-005348) ↗ |
| FY2021 | Dec 31, 2021 | 3,700 | +40.4% | SEC Filing (0001104659-22-025141) ↗ |
| FY2020 | Dec 31, 2020 | 2,635 | +43.1% | SEC Filing (0001104659-21-025751) ↗ |
| FY2019 | Dec 31, 2019 | 1,842 | – | SEC Filing (0001104659-20-023904) ↗ |
Breakdown
What makes up continuous glucose monitoring (cgm — freestyle libre & lingo) worldwide revenue ($m)
Cite this data
StockData. (2026). Abbott Laboratories Continuous Glucose Monitoring (CGM — FreeStyle Libre & Lingo) Worldwide Revenue ($M) ($M), annual FY2019–FY2025 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/cgm-rev-ww
See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.